In the next step of centralized drug procurement, will the price drop be more than 50%?

Since the implementation of centralized procurement with volume in 2018, the Medical Insurance Bureau has achieved remarkable results in the field of centralized drug procurement, which is obvious to the whole society

Going to 2022, under the normalization of centralized procurement, now it is necessary to analyze the current actual situation and how to go next?

01.

01.

Significantly reducing the purchase price and actual price of medicines is the most obvious achievement of the Medical Insurance Bureau's centralized procurement

02.

The first is bidding

03.

From the perspective of the market as a whole, supply cuts and shortages are unavoidable, but they can be prevented, controlled and punished as necessary
.
One is subjective and intentional under-quote or under-received price, and the other is that the cost exceeds the price due to changes in objective conditions
.
For subjective and intentional dumping, government departments should learn from the experience and measures of international anti-dumping, not seek short-term interests, and resolutely stop such illegal acts
.
The prevention of subjective and intentional shortages is to strictly stipulate the identification and investigation of liability for breach of contract in the procurement contract, and include sufficient penalty clauses
.
The company's cost inversion and loss of sales caused by changes in the objective situation should first be borne by the seller
.